Showing 6681-6690 of 9299 results for "".
- Merz North American Provides Educational Grant to Support Dermatology Board Review Systemhttps://practicaldermatology.com/news/20140327-merz_north_american_provides_education_grant_to_support_dermatology_board_review_system/2459291/Merz North America recently provided an educational grant to fund the Derm In-Review system that helps residents prepare for their Board certifying exams free of charge. The system, which has helped prepare more
- Joseph R. Williams Becomes Vice President of Global Marketing for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140326-joseph_r_williams_becomes_vice_president_of_global_marketing_for_caliber_imaging__diagnostics/2459292/Caliber Imaging & Diagnostics named Joseph R. Williams Vice President of Global Marketing. Williams past experience led him to this new position. Previously, he was Director of Market Development at AxsunTechnologies/Volcano Corporation, Senior Director of Global Marketing-Neurosurgery Di
- Merz Aesthetics To Launch New Physician Loyalty Programhttps://practicaldermatology.com/news/20140326-merz_aesthetics_to_launch_new_physician_loyalty_program_my_merz_select/2459293/Merz Aesthetics, a division of Merz North America, announced the upcoming launch of its completely new physician loyalty program, My Merz Select, which will go live on April 1, 2014. My Merz Select is a simple, transparent pro
- Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosaceahttps://practicaldermatology.com/news/20140325-galderma_announces_positive_results_of_phase_3_trials_of_investigational_ivermectin_1_targeting_papulopustular_rosacea/2459295/Galderma Laboratories, L.P. today announced the results of two pivotal phase 3 trials of ivermectin 1%, an investigational drug being evaluated for the treatment of papulopustular (inflammatory) rosacea. The data were presented at a Late-Breaking session of the 72nd annual meeting of the American Ac
- Provectus Biopharmaceuticals Inc. Submits Application to FDA to Receive Breakthrough Therapy Designation for PV-10 for Treatment of Melanomahttps://practicaldermatology.com/news/20140325-provectus_biopharmaceuticals_inc_submits_application_to_fda_to_receive_breakthrough_therapy_designation_for_pv-10_for_treatment_of_melanoma/2459296/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced today that it has applied to the FDA for Breakthrough Therapy Designation (BTD) for PV-10 for the treatment of melanoma. FDA guidelines state that
- Practical Dermatology® Magazine Launches Daily Coverage of Denver Annual Meetinghttps://practicaldermatology.com/news/20140324-practical_dermatology_magazine_launches_daily_coverage_of_denver_annual_meeting/2459297/Bryn Mawr Communications III, LLC's Practical Dermatology® magazine and DermTube.com this weekend launched daily video coverage of the Annual Meeting in Denver with host Joel L. Cohen, MD, FAAD. Dr. Cohen,
- ADAM Names June McKernan “Practice Manager Of The Year”https://practicaldermatology.com/news/20140323-adam_names_june_mckernan_practice_manager_of_the_year/2459299/The Association of Dermatology Administrators and Managers (ADAM) named June McKernan, Administrator, of Patient Preferred Dermatology of Los Alamitos, CA, the recipient of the organization's inaugural Practice Manager of the Year award. She w
- FDA Approves Otezla to Treat Psoriatic Arthritishttps://practicaldermatology.com/news/20140321-fda_approves_otezla_to_treat_psoriatic_arthritis/2459301/The FDA approved Otezla (
- FDA Approves Novartis Drug Xolair for Chronic Idiopathic Urticariahttps://practicaldermatology.com/news/20140321-fda_approves_novartis_drug_xolair_for_chronic_idiopathic_urticaria/2459302/The FDA approved Xolair (Novartis, omalizumab) for the treatment of chronic idiopathic urticaria (CIU) for patients 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy. Xolair is not used to treat other forms of urticaria (
- Novan Announces Positive Phase 2 Results for Novel Acne Treatmenthttps://practicaldermatology.com/news/20140321-novan_announces_positive_phase_2_results_for_novel_acne_treatment/2459303/Novan Therapeutics announced today positive Phase 2 study results of its topical SB204 drug candidate for the treatment of acne vulgaris. Acne is a skin disease that affects more than fifty million people in the United States. The Phas